Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
154
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
stocks
Nvidia: Back in business in China; Raising fair value estimate
stocks
Our top ASX picks in every sector
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,806.80 | 68.50 | -0.77% |
CAC 40 | 7,766.21 | 41.96 | -0.54% |
DAX 40 | 24,060.29 | 100.35 | -0.42% |
Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
FTSE 100 | 8,938.32 | 59.74 | -0.66% |
HKSE | 24,684.28 | 94.16 | 0.38% |
NASDAQ | 20,677.80 | 37.47 | 0.18% |
Nikkei 225 | 39,642.40 | 35.62 | -0.09% |
NZX 50 Index | 12,771.53 | 81.90 | 0.65% |
S&P 500 | 6,243.76 | 24.80 | -0.40% |
S&P/ASX 200 | 8,555.50 | 74.80 | -0.87% |
SSE Composite Index | 3,499.70 | 5.30 | -0.15% |